U.S. Electric Utilities Stock News

NasdaqGS:HUMA
NasdaqGS:HUMABiotechs

Humacyte (HUMA) Valuation Check As Q1 2026 Losses Meet Cost Cuts New Leadership And Global Agreements

Humacyte (HUMA) is back in focus after Q1 2026 results highlighted continued losses alongside restructuring moves, new leadership, fresh international agreements, and upcoming clinical readouts that could influence how investors view the stock. See our latest analysis for Humacyte. The share price has been volatile, with a 1 month share price return of 26.36% but a 1 year total shareholder return that is down 58.48%. This reflects shifting sentiment as investors weigh fresh capital raises,...
OTCPK:RLEA
OTCPK:RLEAAuto Components

Rubber Leaf (OTCPK:RLEA) Turns Q1 EPS Positive Yet Ongoing Losses Challenge Bullish Narratives

Rubber Leaf (OTCPK:RLEA) opened 2026 with Q1 revenue of about US$3.3 million and basic EPS of roughly US$0.01, with the stock trading around US$4.50. Over recent periods, the company has seen quarterly revenue range from US$0 to about US$3.3 million while basic EPS has moved between a loss of roughly US$0.01 and a gain of just under US$0.01. This gives investors a clear view of how sensitive margins have been to shifts in activity levels. See our full analysis for Rubber Leaf. With the...
NasdaqGM:GUTS
NasdaqGM:GUTSMedical Equipment

Fractyl Health (GUTS) Is Up 14.0% After RJVA-001 Human Trial Nod And Q1 Profitability Shift – Has The Bull Case Changed?

In May 2026, Fractyl Health reported first-quarter 2026 net income of US$9.22 million, reversing a prior-year loss, and secured authorization in the Netherlands to begin a Phase 1/2 first-in-human trial of RJVA-001, its Smart GLP-1 gene therapy candidate for type 2 diabetes. An important detail for investors is that this regulatory clearance makes Fractyl a dual clinical-stage company, advancing both its Revita procedure for post‑GLP‑1 weight maintenance and its Rejuva gene therapy platform...
NasdaqGS:PRGS
NasdaqGS:PRGSSoftware

Progress Software Award Spotlights Agentic RAG And Undervalued AI Potential

Progress Software (NasdaqGS:PRGS) has received a 2026 Artificial Intelligence Excellence Award for its Agentic RAG platform. The award recognizes the platform in the Retrieval Augmented Generation (RAG) category for its role in AI driven data solutions. Agentic RAG focuses on converting unstructured data into governed intelligence for enterprise use. For you as an investor, this award draws attention to how Progress Software is positioning itself around operational AI rather than only...